含益生菌四联疗法根除幽门螺杆菌的临床疗效

doi:10.3969/j.issn.1000-8535.2017.01.010

广州医药 ›› 2017, Vol. 48 ›› Issue (1): 38-41.DOI: 10.3969/j.issn.1000-8535.2017.01.010

含益生菌四联疗法根除幽门螺杆菌的临床疗效

彭卫斌¹, 容海鹰¹, 沙卫红², 聂玉强³, 杨元生¹, 李锐清¹, 朱雅丽¹, 张明¹

1 广东药学院附属第二医院(广州新海医院)消化内科(广州 510300)
2 广东省人民医院消化内科(广州 510080)
3 广州医科大学附属广州市第一人民医院消化内科(广州 510180)

收稿日期:2016-11-14 发布日期:2021-12-01
通讯作者: 彭卫斌, E-mail:xiaobin19492003@126.com
基金资助:
广东省医学科学技术研究基金项目(A2016406)

Efficacy of quadruple therapy containing probiotics on eradication of Helicobacter pylori

PENG Weibin¹, RONG Haiying¹, SHA Weihong², NIE Yuqiang³, YANG Yuansheng¹, LI Ruiqing¹, ZHU Yali¹, ZHANG Ming¹

1 Department of Gastroenterology,Guangzhou Xinhai Hospital,The Second Affiliated Hospital of Guangdong University of Pharmacy,Guangzhou 510300,China
2 Department of Gastroenterology,Guangdong General Hospital,Guangzhou 510080,China
3 Department of Gastroenterology,Guangzhou First People's Hospital,Affiliated Hospital of Guangzhou Medical University,Guangzhou 510180,China

Received:2016-11-14 Published:2021-12-01

摘要/Abstract

摘要： 目的探讨含双歧杆菌乳杆菌三联活菌新四联疗法对消化性溃疡患者幽门螺杆菌(Helicobacter pylori, Hp)根除治疗中的疗效。方法将342例Hp阳性的消化性溃疡患者随机分为三个治疗组:A组(三联疗法)、B组(含铋剂四联疗法)及C组(含益生菌四联疗法),疗程均2周。疗程结束4周后复查¹³C-尿素呼气试验评估根除疗效。治疗期间记录患者不良反应发生情况。结果 300例(87.72%)患者按方案完成治疗,A、B及C组治疗完成率分别为85.71%(96/112)、82.50%(99/120)和95.45%(105/110),C组显著高于A及B组(P＜0.05)。在胃溃疡Hp根除率比较中,按意愿(方案)分析,A、B及C组疗法的Hp根除率分别为64.71%(75.86%)、71.43%(85.71%)及84.38%(87.10%),各组间差异无统计学意义(P均>0.05)。在十二指肠球部溃疡Hp根除率比较中,按意愿(ITT)分析,C组(85.90%)明显高于A组(62.82%)及B组(71.79%),差异有统计学意义(χ²=10.893,P=0.001;χ²=4.650,P=0.031);按方案(PP)分析,B组(87.50%)与C组(90.54%)明显高于A组(73.13%),差异有统计学意义(χ²=4.246,P=0.039;χ²=7.304,P=0.007),但B组与C组之间差异无统计学意义(P<0.05)。胃肠道不良反应中,便秘、味觉异常及腹胀的发生率,含益生菌疗法组明显少于另两组,差异有统计学意义(P均<0.05)。结论含双歧杆菌乳杆菌三联活菌新四联疗法能够显著降低传统三联及四联根除疗法的胃肠道不良反应,提高患者依从性,从而提高消化性溃疡患者Hp的根除率。

关键词: 益生菌, 幽门螺杆菌, 三联疗法, 四联疗法, 消化性溃疡

Abstract: Objective To investigate the efficacy of quadruple therapy containing bifidobacterium and lactobacillus triple live bacteria on eradication of Helicobater pylori (Hp) among the patients with peptic ulcer. Methods 342 Hp-infected peptic ulcer patients were randomly divided into three groups:A, B and C. The patients in group A were treated with standard triple therapy. The patients in group B and group C were treated with Colloidal Bismuth Subcitrate and Bifidobacterium and Lactobacillus combined with standard triple therapy, respectively. All patients in three groups were treated for 14 days. In the 4th week after end of treatment, Hp eradication was assessed by ¹³C-urea breath test. Adverse effects during the course of treatment were recorded. Results A total of 300(87.72%) patients completed the treatment. The completion rates in group A, B and C were 85.71%(96/112), 82.50%(99/120) and 95.45%(105/110) respectively, and the completion rate in group C were significantly higher than that in group A and group B(P<0.05). With intention to treat and per-protocol analysis in gastric ulcer, the eradication rates of group A, B and C were 64.71%(75.86%), 71.43%(85.71%)and 84.38%(87.10%) respectively, but there were not significant difference in the three groups(P>0.05). With intention to treat analysis in duodenal ulcer, the Hp eradication rate in group C was 85.90%, which was significantly higher than that in group A (62.82%;χ²=10.893,P=0.001) and in group B (71.79%;χ²=4.650,P=0.031). With per-protocol analysis in duodenal ulcer, the Hp eradication rate was 90.54% in group C and 87.50% in group B. No Obviously difference was found between group B and group C (P<0.05), but both were higher than that in group A(73.13%) (χ²=4.246,P=0.039;χ²=7.304,P=0.007). The incidence of adverse reactions including constipation, taste distortion and bloating in group C were significantly lower than those in the other two groups (P<0.05). Conclusion The quadruple therapy containing bifidobacterium and lactobacillus triple live bacteria can obviously enhance the patient's compliance and decrease the adverse reactions, thereby may increase the Hp eradication rate among the patients with peptic ulcer.

Key words: Probiotics, Helicobacter pylori, Triple therapy, Quadruple therapy, Peptic ulcer

彭卫斌, 容海鹰, 沙卫红, 聂玉强, 杨元生, 李锐清, 朱雅丽, 张明. 含益生菌四联疗法根除幽门螺杆菌的临床疗效[J]. 广州医药, 2017, 48(1): 38-41.

PENG Weibin, RONG Haiying, SHA Weihong, NIE Yuqiang, YANG Yuansheng, LI Ruiqing, ZHU Yali, ZHANG Ming. Efficacy of quadruple therapy containing probiotics on eradication of Helicobacter pylori[J]. Guangzhou Medical Journal, 2017, 48(1): 38-41.

参考文献

[1] COVER T L, BLASER M J. Helicobacter pylori in health and disease[J]. Gastroenterol, 2009,136(6):1863-1873.
[2] MALFERTHEINER P, MEGRAUD F, O'MORAIN C A, et al. European Helicobacter Study Group. Management of Helicobacter pylori infection-the Maastricht IV/ Florence Consensus Report[J]. Gut, 2012,61(5):646-664.
[3] 张万岱,胡伏莲,萧树东,等.中国自然人群幽门螺杆菌感染的流行病学调查[J]. 现代消化及介入诊疗,2010,15(5):265-270.
[4] ZHENG Q, CHEN W J, LU H, et al. Comparison of the efficacy of triple versus quadruple therapy on the eradication of Helicobacter pylori and antibiotic resistance[J]. J Dig Dis, 2010,11(5):313-318.
[5] MALFERTHEINER P, BAZZOLI F, DELCHIER J C, et al. Pylera Study Group. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised,open-label, non-inferiority, phase 3 trial[J]. Lancet, 2011,377(9769):905-913.
[6] LV Z, WANG B, ZHOU X, et al. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: A meta-analysis[J]. Exp Ther Med, 2015,9(3):707-716.
[7] PATEL A, SHAH N, PRAJAPATI J B. Clinical application of probiotics in the treatment of Helicobacter pylori infection-A brief review[J]. J Microbiol Immunol Infect, 2014,47(5):429-437.
[8] MOLINA-INFANTE J, GISBERT J P. Probiotics for Helicobacter pylori eradication therapy: not ready for prime time[J]. Rev Esp Enferm Dig,2013,105(8):441-444.
[9] OH B, KIM B S, KIM J W, et al. The Effect of Probiotics on Gut Microbiota during the Helicobacter pylori Eradication:Randomized Controlled Trial[J]. Helicobacter, 2016,21(3):165-174.
[10] 中华医学会消化病学分会幽门螺杆菌学组/全国幽门螺杆菌科研协作组.中国幽门螺杆菌耐药状况以及耐药对治疗的影响-全国多中心临床研究[J]. 胃肠病学,2007,12(9):525-530.
[11] YANG Y J, SHEU B S. Probiotics-containing yogurts suppress Helicobacter pylori load and modify immune response and intestinal microbiota in the Helicobacter pylori-infected children[J]. Helicobacter, 2012,17(4):297-304.
[12] WANG Z H, GAO Q Y, FANG J Y. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifi-dobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy[J]. J Clin Gastroenterol, 2013,47(1):25-32.
[13] DEGUCHI R, NAKAMINAMI H,RIMBARA E, et al. Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapy[J]. J Gastroenterol Hepatol, 2012,27(5): 888-892.

含益生菌四联疗法根除幽门螺杆菌的临床疗效

Efficacy of quadruple therapy containing probiotics on eradication of Helicobacter pylori

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 6

编辑推荐

Metrics

本文评价

[1]	张春燕, 张赐理. 幽门螺杆菌感染与儿童过敏性紫癜患病及预后的相关性研究[J]. 广州医药, 2018, 49(4): 79-81.
[2]	李燕君, 杨小霞. 优质护理对消化性溃疡患者的疗效及护理满意度影响分析[J]. 广州医药, 2016, 47(6): 59-61.
[3]	陈航远, 谭其平, 蒋宇敏. 含多西环素四联疗法对幽门螺杆菌感染消化性溃疡的疗效研究[J]. 广州医药, 2016, 47(5): 86-87.
[4]	廖素环, 李啸峰, 江堤, 路静, 邓惠钊. 消化性溃疡8592例内镜分析[J]. 广州医药, 2016, 47(2): 52-55.
[5]	周丽丽, 魏良洲. 幽门螺杆菌感染与反流性食管炎关系的研究[J]. 广州医药, 2016, 47(1): 46-48.
[6]	黄鲁, 沈洁. 幽门螺杆菌感染与年龄及血脂异常的相关性[J]. 广州医药, 2016, 47(1): 75-77.